News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
This opens up a huge market for the company’s Magnezis implants in India
The company plans to expand its portfolio in regulated markets aggressively
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The transaction is anticipated to close in the first quarter of 2022
A total of 8308 stores are open across India and medicines are priced at affordable rates
FUJIFILM will distribute iSWAB bio sampling technologies in Japan
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
Subscribe To Our Newsletter & Stay Updated
